口服地西他滨联合西达尿苷用于极高危急性髓系白血病或骨髓增生异常综合征造血干细胞移植后维持治疗(GFM-DACORAL-DLI):一项多中心、单臂、2期试验
在法国12个中心开展的多中心单臂2期试验中,51例极高危急性髓系白血病或骨髓增生异常综合征患者接受异基因造血干细胞移植,其中34例接受口服地西他滨联合西达尿苷(ASTX727)维持治疗;前28例可评估患者移植后1年无病生存率为70.4%(95%CI 55.1-89.9),3级及以上不良事件以血液学毒性为主,发生1例治疗相关死亡。
要点
- 前28例接受ASTX727维持治疗者移植后1年无病生存率为70.4%(95%CI 55.1-89.9)。
- 34例接受维持治疗者中25例(74%)发生3级及以上不良事件,多为血液学毒性。
- 14例(41%)完成10个周期,7例至少接受一次供者淋巴细胞输注。
核心结论
- ASTX727可能成为极高危急性髓系白血病或骨髓增生异常综合征患者造血干细胞移植后的潜在治疗选择。
- 作者认为需进一步研究以确立该治疗方案的疗效和安全性。
研究设计与样本
- 多中心、单臂、2期研究(GFM-DACORAL-DLI),在法国12个中心开展。
- 纳入18-70岁、ECOG体能状态0-2、无移植禁忌证且属极高危疾病的患者,于移植前5-45天入组。
- ASTX727自移植后第40天起口服给药,剂量递增(西达尿苷100 mg联合地西他滨35 mg,从每周期1天增至3天),最多10个周期。
- 第4周期后无禁忌证者推荐供者淋巴细胞输注。
- 主要终点为移植后1年无病生存率,在前28例接受ASTX727治疗的患者中评估;安全性在所有至少接受一疗程ASTX727的参与者中评估。
主要发现
- 51例接受移植者中位年龄62.0岁(IQR 56.5-65.0),女性22例(43%)、男性29例(57%)。
- 34例接受ASTX727维持治疗,其中7例至少接受一次供者淋巴细胞输注,14例(41%)完成10个周期。
- 中位随访12.6个月(IQR 10.3-14.3)。
- 前28例接受ASTX727治疗者移植后1年无病生存率为70.4%(95%CI 55.1-89.9)。
- 34例中25例(74%)发生3级及以上不良事件,最常见为血液学毒性:中性粒细胞减少21例(62%)、血小板减少8例(24%)、贫血4例(12%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步研究以确立该治疗方案的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of a hypomethylating agent with donor lymphocyte infusion as maintenance therapy after haematopoietic stem-cell transplantation (HSCT) in acute myeloid leukaemia and myelodysplastic syndrome might reduce the risk of relapse. We aimed to evaluate the activity and safety of oral decitabine and cedazuridine (ASTX727) as maintenance after allogeneic HSCT in patients with acute myeloid leukaemia or myelodysplastic syndrome at very high risk of relapse post-transplantation. METHODS: We conducted a multicentre, single-arm, phase 2 study (GFM-DACORAL-DLI) at 12 centres in France. We enrolled patients aged 18-70 years with an Eastern Cooperative Oncology Group performance status of 0-2, without contraindication for HSCT, and with very high-risk disease (poor or very poor prognosis according to the revised International Prognostic Scoring System for myelodysplastic syndrome, adverse risk according to the 2017 European LeukemiaNet classification for acute myeloid leukaemia; unfavourable genetics; and acute myeloid leukaemia post-myelodysplastic syndrome or post-myeloproliferative neoplasm, or relapsing less than 2 years after complete response). Patients were included 5-45 days before transplantation. ASTX727 was orally administered at escalating doses (100 mg cedazuridine plus 35 mg decitabine starting at 1 day per cycle and increasing to 3 days) from day 40 post-HSCT, up to ten cycles. Donor lymphocyte infusion was recommended when patients had no contraindication after cycle 4. The primary endpoint was disease-free survival at 1 year after HSCT, assessed in the first 28 enrolled patients treated with ASTX7277. Safety was assessed in all participants who received at least one course of ASTX727. This study was registered with ClinicalTrials.gov (NCT04857645); enrolment is complete but follow-up is ongoing. FINDINGS: Between Sept 28, 2021, and March 1, 2023, 59 patients were screened and 51 patients underwent allogeneic HSCT (median age 62·0 years [IQR 56·5-65·0]; 22 [43%] female, 29 [57%] male). 34 patients received maintenance treatment with ASTX727; seven of them received at least one donor lymphocyte infusion. 14 (41%) patients completed the ten cycles. Median follow-up was 12·6 months (IQR 10·3-14·3). Among the first 28 enrolled patients treated with ASTX727, disease-free survival at 1 year after HSCT was 70·4% (95% CI 55·1-89·9). The most frequent grade 3 or worse adverse events were haematological, occurring in 25 (74%) of 34 patients (21 [62%] neutropenia, eight [24%] thrombocytopenia, four [12%] anaemia). Serious adverse events occurred in 14 (41%) of 34 patients, and were haematological in eight patients and gastrointestinal in three patients. One treatment-related death, due to thrombocytopenia, occurred. INTERPRETATION: ASTX727 could be a potential treatment option after HSCT in patients with acute myeloid leukaemia or myelodysplastic syndrome at very high risk of relapse. Further investigation is warranted to establish the efficacy and safety of this therapeutic approach. FUNDING: Taiho Oncology and Astex Pharmaceuticals.
引用
- Robin M, D'Aveni M, Stamatoullas A, et al. Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025. PMID: 40784355. doi:10.1016/S2352-3026(25)00172-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。